The 2nd AACR-IASLC Joint Conference on the Molecular Origins of Lung Cancer: Pro

描述（由申请人提供）：美国癌症研究协会（AACR）和国际肺癌研究协会（IASLC）正在联合组织第二次肺癌分子起源会议：个性化预防和治疗的前景，以跟进2010年成功的会议。第二次会议将于2012年1月8日至11日在加利福尼亚州圣地亚哥的圣地亚哥万豪酒店举行，重点关注肺癌研究的分子和转化方面。肺癌仍然是美国癌症死亡的最常见原因。美国癌症协会估计，2010年有222，520例肺癌新发病例（自2009年以来有所增加），死亡人数为158，080人1。过去15年的研究提供了对不同类型非小细胞肺癌（NSCLC）分层的分子细微差别的见解。在过去，一种用细胞毒性化疗药物靶向所有NSCLC的方法，一种“一刀切的方法”，提供了一个小的可测量的获益，但通常缓解率低于20%2。最近，发现了NSCLC的常见分子亚型，允许更有针对性和基于亚型的治疗选择。NSCLC中研究最多的遗传变异是编码EGFR的基因突变。与没有EGFR突变的患者相比，具有这种突变的患者对EGFR酪氨酸激酶抑制剂（如吉非替尼或厄洛替尼）的应答率更高。同样，在2010年，ALK融合的NSCLC分子亚型作为临床相关和可治疗的致癌突变出现在最前沿。ALK融合亚型NSCLC对不同药物的反应不同于EGFR突变病变（克唑替尼的缓解率约为57%），这突出表明需要了解个体的肿瘤基因型以获得最佳治疗。需要多学科关注的肺癌研究领域的新进展包括：赋予治疗抗性的基因突变，肺癌的其他分子亚型，以及2010年11月NCI国家肺筛查试验结果中报告的早期检测筛查的可能性。本次会议将汇集来自肺癌研究的基础，临床和转化学科的300多名研究人员，并为他们提供一个场所，讨论他们的最新进展，测试新的假设，并建立新的合作。与我们过去成功的会议一样，演讲者还将讨论化学预防的分子机制，早期检测，癌症干细胞，表观遗传学，新型疗法，临床试验结果和许多其他主题。这次会议不仅是AACR和IASLC这两个致力于癌症研究的组织的动态合作，也是对这种疾病进行全面研究和治疗所需的许多类型的科学家和倡导者的动态合作。 公共卫生相关性：肺癌仍然是美国癌症死亡的最常见原因，分别占男性和女性癌症相关死亡的29%和26%。美国癌症协会估计，2010年有222，520例肺癌新发病例，占所有确诊癌症新发病例的14-15%（自2009年以来有所增加）。鉴于肿瘤中复杂的潜在遗传改变和环境因素的复杂性，从患者倡导者，医生，基础，翻译和临床科学家的角度更好地了解疾病至关重要。该论坛由AACR和IASLC合作提供，对于开发诊断，研究和治疗肺癌的新方法至关重要。

DESCRIPTION (provided by applicant): The American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC) are jointly organizing a second conference on the Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy to follow up on the successful 2010 conference. This second conference will take place January 8-11, 2012 at the San Diego Marriott Hotel & Marina in San Diego, CA and will focus on the molecular and translational aspects of lung cancer research. Lung cancer remains the most common cause of cancer death in the United States. The American Cancer Society estimates there were 222,520 new cases of lung cancer in 2010 (an increase since 2009) with 158,080 deaths1. The last 15 years of research have provided insight into the molecular nuances that stratify different types of non-small-cell lung cancer (NSCLC). In the past an approach to target all NSCLC with cytotoxic chemotherapeutic agents, a "one size fits all approach," provided a small measureable benefit but often with response rates of less than 20%2. Most recently, common molecular subtypes of NSCLC have been found, allowing for more targeted and subtype-based treatment selection. The most studied genetic variant in NSCLC is mutation in the gene encoding EGFR. Patients with this mutation have a better response rate to EGFR tyrosine kinase inhibitors, such as gefitinib or erlotinib, than those without the EGFR mutation. Similarly in 2010, the molecular subtype of NSCLC with ALK fusions emerged to the forefront as a clinically relevant and treatable oncogenic mutation. The ALK fusion subtype of NSCLC responds to a different drug than those lesions with an EGFR mutation (~57% response rate to crizotinib), highlighting the need to understand an individual's tumor genotype for optimal treatment. Emerging advances in the field of lung cancer research that require multi-disciplinary attention are: genetic mutations that confer resistance to treatment, the other molecular sub-types of lung cancer, and the possibility of screening for early detection reported in the results of the November 2010 NCI National Lung Screening Trial. This conference will bring together over 300 investigators from the basic, clinical, and translational disciplines of lung cancer research and provide them with a venue to discuss their recent advances, test new hypotheses, and establish new collaborations. As in our past successful conference, presenters will also discuss molecular mechanisms of chemoprevention, early detection, cancer stem cells, epigenetics, novel therapeutics, clinical trial results, and many other topics. This conference is not only a dynamic collaboration of the AACR and the IASLC, two organizations committed to the study of cancer, but also a dynamic collaboration of the many types of scientists and advocates that are needed for the well-rounded study and treatment of this disease. PUBLIC HEALTH RELEVANCE: Lung cancer remains the most common cause of cancer death in the United States and accounts for 29% and 26% of cancer-related deaths in men and women, respectively. The American Cancer Society estimates there were 222,520 new cases of lung cancer in 2010, accounting for ~14-15% of all new cases of cancer diagnosed (an increase since 2009)1. Given the complex underlying genetic alterations in tumors and the complication of contributing environmental factors, it is critical to gain a better understanding of the disease from the view of patient advocates, physicians, basic, translational, and clinical scientists. This forum, provided by the collaboration of AACR and IASLC, will be critical for developing new ways of diagnosing, studying, and treating lung cancer.